Last reviewed · How we verify
NCT05592535
Outcomes With Fractional Flow Reserve in Chronic Coronary Syndrome
trial testing Coronary revascularization in Chronic Coronary Syndrome in 5,000 participants. Completed in 1 June 2020.
1 June 2020
Quick facts
| Lead sponsor | Uppsala University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 June 2015 |
| Primary completion | 1 June 2020 |
| Estimated completion | 1 June 2020 |
Drugs / interventions tested
- Coronary revascularization
Conditions studied
- Chronic Coronary Syndrome — all drugs for Chronic Coronary Syndrome →
Sponsor
Uppsala University
Who can join
Eligibility, any sex, with Chronic Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The use of fractional flow reserve (FFR) to assess the functional relevance of coronary stenoses has been demonstrated to reduce the risk urgent revascularization in chronic coronary syndrome patients.\[1\] The goal of this study is to assess whether the utility of using FFR during percutaneous coronary intervention (PCI) in chronic coronary syndrome patients is confirmed in a real-life scenario. This study will implement a regression discontinuity design (RDD). RDD is a quasi-experimental study design able to provide robust findings on causality using observational data.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05592535
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Coronary Syndrome
Currently open trials in the same condition.
- NCT07195149 — Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Followin · Phase 3 · recruiting
- NCT07182799 — Starring Optical Coherence Tomography During Percutaneous Coronary Intervention Guidance · active not recruiting
- NCT07291609 — Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes · recruiting
- NCT06896708 — Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patie · NA · recruiting
- NCT07020858 — FAPI Imaging Predicts Adverse Cardiac Events in Chronic Total Occlusion · recruiting
Other Uppsala University trials
Trials by the same sponsor.
- NCT07517185 — The HIt HArd and hiT Early in Multiple Sclerosis Trial · Phase 2 · not yet recruiting
- NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
- NCT07461636 — Robotic-Assisted Pedicle Screw Placement in Spine Surgery · recruiting
- NCT07273409 — Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not · NA · recruiting
- NCT07352683 — Open TAP-block in Pediatric Abdominal Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05592535 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uppsala University
- Last refreshed: 24 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05592535.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing